Drug therapy articles from across Nature Portfolio

Valtteri Muroke discusses the LoDoCo trial, in which treatment with low-dose colchicine was shown to reduce cardiovascular end points in patients with stable coronary artery disease, identifying anti-inflammatory therapy as an effective strategy for the secondary prevention of cardiovascular events.

New evidence from five randomized trials suggests that withholding β-blockers after myocardial infarction (MI) is safe for carefully selected, low-risk patients. However, even if β-blockers are not required to treat ventricular dysfunction, hypertension or arrhythmias, it might still be wiser to continue treatment during the vulnerable period immediately after MI and withdraw treatment several months later.